内分泌疾病属于一个广泛的类别，即激素分泌过多或过少，组织对激素的反应改变或内分泌组织¹产生的肿瘤。其中一些疾病会影响新陈代谢，如在世界范围内发病率稳步上升的糖尿病损害生育能力以及生长。
 
山德士致力于为内分泌学界提供支持，为医疗专业人士及病人护理人员提供支持。山德士还致力于增加医生和患者对内分泌高质量生物药物的更多选择。
 
山德士2006年上市并获得EMA批准的Omnitrope^®（重组人类生长激素，rhGH，Somatropin），是世界上首个生物类似药。³
 
此外，我们正努力在未来几年将多种胰岛素生物类似药推向市场。⁴

1. Melmed S, et al. (eds). Williams Textbook of Endocrinology. 13th edition. Philadelphia: Elsevier; 2016
2. World Health Organization. (‎2016)‎. Global report on diabetes: executive summary. World Health Organization.  https://apps.who.int/iris/handle/10665/204874 [Accessed February 2019]
3. European Medicines Agency. Omnitrope® Summary of Product Characteristics. Available from: https://www.ema.europa.eu/en/documents/product-information/omnitrope-epar-product-information_en.pdf [Accessed February 2019]
4. Sandoz International GmbH. Sandoz enters into commercialization and supply agreement for insulin biosimilars, anticipating growing demand as diabetes burden rises. Available from: https://www.sandoz.com/news/media-releases/sandoz-enters-commercialization-and-supply-agreement-insulin-biosimilars-anticipating-growing-demand-diabetes-burden-rises [Accessed February 2019]